Data support adding suprachoroidal injection to anti-VEGF for RVO.

The article focuses on a study which showed that the combination therapy with suprachoroidal triamcinolone acetonide injection plus an intra vitreal anti-vascular endothelial growth factor (VEGF) agent is a promising approach for treating eyes with macular edema (ME) and vision loss associated with retinal vein occlusion (RVO). Topics discussed include the aflibercebt injections received by the study participants and the changes in best-corrected visual acuity (BCVA) of study participants.